Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept(®), Roche): overview

Roche's protease inhibitor nelfinavir mesylate (Viracept(®)) produced between March 2007-June 2007 was found to contain elevated levels of ethyl methanesulfonate (EMS), a known mutagen (alkylator) – leading to a global recall of the drug. EMS levels in a daily dose (2,500 mg Viracept/day) were...

Descripción completa

Detalles Bibliográficos
Autores principales: Pozniak, Anton, Müller, Lutz, Salgo, Miklos, Jones, Judith K, Larson, Peter, Tweats, David
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731786/
https://www.ncbi.nlm.nih.gov/pubmed/19660105
http://dx.doi.org/10.1186/1742-6405-6-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731786/
https://www.ncbi.nlm.nih.gov/pubmed/19660105
http://dx.doi.org/10.1186/1742-6405-6-18

Ejemplares similares